SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Submission of Matters to a Vote of Security Holders

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below

Item 5.07

Submission of Matters to a Vote of Security Holders.
The Company held its Annual Meeting of Stockholders (the Annual
Meeting) on June 13, 2017 at the Companys corporate headquarters
located at 11500 S. Eastern Avenue, Suite 240, Henderson, Nevada
89052. As of April 17, 2017, the record date for the Annual
Meeting, a total of 80,443,922 shares were entitled to vote, of
which a total of 70,980,202 shares were present in person or by
proxy at the Annual Meeting constituting a quorum for the conduct
of business thereat.
The following sets forth detailed information regarding the voting
results at the Annual Meeting for each of the matters voted upon by
the stockholders. These matters are described in more detail in the
Company’s definitive proxy statement on Schedule 14A, which the
Company filed with the Securities and Exchange Commission on April
17, 2017 (the “Proxy Statement”).
Proposal No. 1:
The Companys stockholders elected>each of the seven nominees
named below to serve on the Companys Board of Directors for a
one-year term expiring at the annual meeting of stockholders in
2018 and until their respective successors are duly elected and
qualified, or until their earlier resignation or removal.
Nominee
Votes For
Votes Withheld
Broker Non-Votes
Raymond W. Cohen
37,223,271
17,098,120
16,658,811
Gilles R. Gagnon
41,004,858
13,316,533
16,658,811
Stuart M. Krassner
38,013,573
16,307,818
16,658,811
Luigi Lenaz
26,225,190
28,096,201
16,658,811
Anthony E. Maida
37,003,558
17,317,833
16,658,811
Rajesh C. Shrotriya
40,804,085
13,517,306
16,658,811
Dolatrai Vyas
37,613,210
16,708,181
16,658,811
Proposal No. 2:
The Companys stockholders did not approve by advisory vote the
executive compensation detailed in the Proxy Statement.
Votes For
Votes Against
Abstentions
Broker Non-Votes
23,752,273
30,309,362
259,756
16,658,811

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Proposal No. 3:
The Companys stockholders voted that the frequency of the advisory
vote on executive compensation should be every year, by a vote as
follows.
Annual
Bi-Annual
Tri-Annual
Abstentions
44,264,130
188,932
9,724,272
144,057
Based on these results, the Company has decided to hold a
stockholder advisory vote to approve executive compensation every
year, until the next stockholder advisory vote on the frequency of
the stockholder advisory vote to approve executive compensation. A
stockholder advisory vote on the frequency of stockholder advisory
votes to approve executive compensation is required to be held at
least once every six years.
Proposal No. 4:
The Companys stockholders approved the ratification of Deloitte
Touche LLP as the independent registered public accounting firm for
the year ending December 31, 2017.
Votes For
Votes Against
Abstentions
Broker Non-Votes
69,866,460
752,040
361,702
Proposal No. 5:
The Companys stockholders approved a stockholder proposal regarding
majority voting, as detailed in the Proxy Statement.
Votes For
Votes Against
Abstentions
Broker Non-Votes
46,720,648
7,203,144
397,599
16,658,811
The Company’s Board of Directors, including the Compensation
Committee, acknowledges the votes for the foregoing proposals at
the annual meeting, including the advisory vote on executive
compensation, and looks forward to continuing a constructive
dialogue with the stockholders in the coming months.


About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

An ad to help with our costs